Horizon Therapeutics (Horizon Therapeutics) Effective Interest Rate on Debt % : 1.89% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Horizon Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Jun. 2023 was $48 Mil. Horizon Therapeutics's average total debt for the quarter that ended in Jun. 2023 was $2,559 Mil. Therefore, Horizon Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2023 was 1.89%.

Horizon Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Horizon Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Effective Interest Rate on Debt % Chart

Horizon Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

6.41

5.36

5.06

4.52

3.24

Horizon Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															3.33	3.50	2.89	2.42	1.89

Competitive Comparison of Horizon Therapeutics's Effective Interest Rate on Debt %

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Horizon Therapeutics's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Effective Interest Rate on Debt % falls into.

Horizon Therapeutics Effective Interest Rate on Debt % Calculation

Horizon Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2022 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2021 )	+	Total Debt (A: Dec. 2022 ))	/ count )
=	-1 * -83.707	/	( (2587.233	+	2578.837)	/ 2 )
=	-1 * -83.707	/	2583.035
=	3.24 %

where

	Total Debt (A: Dec. 2021 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2571.233	+	16
=	2587.233

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2562.837	+	16
=	2578.837

Horizon Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Mar. 2023 )	+	Total Debt (Q: Jun. 2023 ))	/ count )
=	-1 * -48.392	/	( (2560.23	+	2557.458)	/ 2 )
=	-1 * -48.392	/	2558.844
=	1.89 %

where

	Total Debt (Q: Mar. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2544.23	+	16
=	2560.23

	Total Debt (Q: Jun. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2541.458	+	16
=	2557.458

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jun. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Horizon Therapeutics (NAS:HZNP) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Horizon Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Horizon Therapeutics (Horizon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 St. Stephen’s Green, Dublin, IRL, D02 E2X4

Website

https://www.horizontherapeutics.com

Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Executives

Andy Pasternak	officer: EVP and Chief Business Officer	C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox	officer: EVP, Chief Financial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman	officer: EVP & Chief Medical Officer	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny	officer: Chief Accounting Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton	officer: EVP, General Counsel	C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z.	officer: EVP, Research & Development	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director, officer: President, Chairman and CEO	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi	officer: Chief Commercial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher	officer: EVP Finance	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin	officer: EVP, Technical Operations	C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh	officer: Principal Accounting Officer	C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze	officer: EVP, Corporate Dev't.	C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler	officer: EVP, General Counsel	C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel	director	TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000